Hello, page-9

to answer the legitimate question your raised in another thread

Q&A 21min

Q: "you got the BLA coming as you said second half of calendar 2023, when could we reasonably see some revenues from that product"

A: "with the breakthrough designation, and the characteristics of the patient population that we're going after, we'll be eligible for a fast review process; we haven't asked for that yet but got a pre-BLA meeting, that would be one of the topics of conversation; we're seeing high degree of engagement from the FDA as well as from our european scientific advisors and feedback is just being exciting and positive; so realistically by the middle of next year we should be in the market with this product; as to reimbursement, we got 4 entry points for the CMS, so subject to how guidelines support the adoption, we can expect to see it very quickly; I think the key thing to remember is renal cancer product follows on the success we've had with Illuccix" etc.